Nuwellis Receives Notice of Allowance of a New U.S. Patent Strengthening Vivian(TM) Pediatric System with Advanced Clamp Safety Technology
MWN-AI** Summary
Nuwellis, Inc. (Nasdaq: NUWE), a medical technology firm focused on cardio-renal conditions, has recently received a notice of allowance from the U.S. Patent and Trademark Office for a new patent pertaining to advanced safety mechanisms in blood return line clamps used in extracorporeal blood filtration systems. This innovation is particularly significant for the company's Vivian™ Pediatric Continuous Renal Replacement Therapy (CRRT) System, designed to enhance safety for pediatric patients.
The newly patented technology improves the performance of automated clamps, which are critical to safety protocols by preventing air embolism and pressure imbalances. Notably, it adjusts clamping force dynamically according to environmental conditions, conditions the tubing for optimal stability, and includes added thermal insulation. These enhancements are aimed at providing greater safety and reliability in pediatric therapies, addressing the unique needs of smaller patients.
John Erb, CEO of Nuwellis, emphasized the importance of safety and precision in the design of the Vivian system, stating that this new patent underscores their commitment to intelligent engineering that inspires clinician confidence. This patent adds to a growing intellectual property portfolio for the Vivian system and aligns with Nuwellis' pediatric technology roadmap, which previously included a September 2025 patent for hemolysis sensing in extracorporeal circuits.
The company is progressing in the pediatric fluid management sector, supported by NIH grant-funded research and insights from their Aquadex® system, which has been used in pediatric patients. Nuwellis remains focused on developing innovative solutions for fluid overload, demonstrating a strong commitment to pediatric innovation and safety in medical devices. The Vivian system, still under development, showcases a user-friendly interface designed to assist healthcare providers in delivering precise and effective care for vulnerable young patients.
MWN-AI** Analysis
Nuwellis, Inc. (Nasdaq: NUWE) recently received a notice of allowance for a new patent concerning advanced safety mechanisms in its Vivian Pediatric Continuous Renal Replacement Therapy (CRRT) System. This development highlights the company's commitment to enhancing safety in pediatric fluid management, a critical area given the vulnerability of young patients. The patent's innovative clamp safety technology promises to mitigate risks associated with air embolisms and pressure imbalances, factors critical in pediatric extracorporeal treatments.
From a market perspective, this news is likely to bolster investor confidence and position Nuwellis favorably against competitors. The addition of this patent to Nuwellis' intellectual property portfolio emphasizes its capacity for innovation in a niche market, potentially attracting interest from institutional investors focusing on healthcare and medical technologies.
Moreover, the company's strategic focus on pediatric applications aligns well with current trends in healthcare emphasizing precision medicine and patient safety. The integration of funding from the National Institute of Health (NIH) for research further demonstrates credibility and enhances the company’s growth prospects.
In terms of stock action, investors should watch for short-term fluctuations as the market digests this patent news alongside overall trends in medical device adoption. If Nuwellis can successfully commercialize Vivian while expanding its market presence, the stock could see significant upside over the long term.
However, potential investors should consider risks, including competition in the medical device field, execution challenges, and the regulatory landscape associated with bringing new devices to market. A cautious entry strategy, possibly after further updates on Vivian's commercialization progress and clinical outcomes, could be prudent for those looking to invest in NUWE. Overall, the patent allowance is a positive signal within a broader narrative of innovation in critical pediatric care.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
MINNEAPOLIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company committed to delivering solutions for patients with cardio-renal conditions, addressing the critical interplay between the heart and kidneys, today announced that the United States Patent and Trademark Office has issued Nuwellis a notice of allowance for a new patent covering advanced safety mechanisms for blood return line clamps used in extracorporeal blood filtration systems, including the company’s Vivian™ Pediatric Continuous Renal Replacement Therapy (CRRT) System currently in development.
Many extracorporeal blood filtration systems rely on automated clamps as part of their safety design to prevent air embolism or pressure imbalances. The newly patented technology enhances this core function by dynamically adjusting clamping force based on environmental factors, automatically reconditioning the tubing under defined thermal conditions, and adding thermal insulation for improved material stability. Together, these innovations strengthen one of the most critical safety components in pediatric extracorporeal therapy—ensuring consistent, reliable protection for the smallest patients.
“Every element of the Vivian system is being designed with safety and precision in mind,” said John Erb, Chief Executive Officer of Nuwellis. “This new patent reinforces our commitment to advancing the pediatric platform with intelligent engineering that supports both clinician confidence and patient safety.”
This patent adds to a growing portfolio of intellectual property supporting the Vivian system and Nuwellis’ pediatric technology roadmap, following the September 2025 patent issuance for hemolysis sensing in extracorporeal circuits. Together, these advancements reflect meaningful progress toward safer, smarter, and more responsive pediatric fluid management.
The company’s innovation in this space is further supported by National Institute of Health (NIH) grant-funded research and the use of the Aquadex® system in pediatric patients weighing 20 kg or more, helping to inform design decisions and guide future clinical applications for Vivian.
“Our advancements in both Aquadex and Vivian underscore a continuous commitment to pediatric innovation,” added Erb. “We’re building a foundation that spans today’s therapies and tomorrow’s breakthroughs in fluid management.”
With each patent, Nuwellis continues to strengthen its leadership in precision fluid management and its mission to deliver safer, smarter solutions for patients across the cardio-renal continuum.
For more information, visit www.nuwellis.com .
About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovation. The company is focused on commercializing the Aquadex SmartFlow® system for ultrafiltration therapy. Nuwellis is headquartered in Minneapolis, with a wholly owned subsidiary in Ireland. For more information visit www.nuwellis.com or visit us on LinkedIn or X, formerly known as Twitter.
About the Aquadex SmartFlow® System The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
About Vivian Vivian is a purpose-built pediatric CRRT system designed for neonates and children. The platform targets an extracorporeal blood volume of 29–67 mL and features integrated hematocrit and SvO? sensors for real-time monitoring. Vivian brings three therapies—Ultrafiltration (UF), Continuous Veno-Venous Hemofiltration (CVVH), and Continuous Veno-Venous Hemodialysis (CVVHD)—onto a single platform with closed-loop ultrafiltration control tailored to patient weight. A guided, clinician-informed interface with on-screen prompts streamlines setup and reduces training burden, while a 6-port circuit provides flexible vascular-access options. Intended for patients 2.5–20 kg, Vivian was developed with direct input from pediatric ICU and nephrology teams to prioritize safety, precision, and simplicity for the most fragile patients.
Disclaimer: Vivian is an investigational device, under development, and not available for sale. Features and specifications are subject to change.
Forward-Looking Statements Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the new market opportunities and anticipated growth in 2025 and beyond. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our ability to execute on our commercialization strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Nuwellis does not assume any obligation to publicly update or revise any forward-looking statements, whether due to new information, future events or otherwise.
For further information, please contact:
Investor Relations:
ir@nuwellis.com
Media Contact:
Leah McMullen
Director of Communications
Leah.mcmullen@nuwellis.com
FAQ**
How does the newly patented technology for blood return line clamps enhance the safety of the Vivian™ Pediatric CRRT System developed by Nuwellis Inc. (NUWE)?
What role did the National Institute of Health (NIH) grant-funded research play in informing the design decisions of Nuwellis Inc. (NUWE) and the Vivian system?
In what ways could Nuwellis Inc. (NUWE) leverage its growing portfolio of patents to strengthen its commercial position in pediatric fluid management technologies?
Can Nuwellis Inc. (NUWE) provide insights into the anticipated market acceptance and potential growth opportunities for its Aquadex SmartFlow® system and Vivian pediatric platform in the coming years?
**MWN-AI FAQ is based on asking OpenAI questions about Nuwellis Inc. (NASDAQ: NUWE).
NASDAQ: NUWE
NUWE Trading
-3.52% G/L:
$1.2832 Last:
25,984 Volume:
$1.36 Open:
